Context dependent non canonical WNT signaling mediates activation of fibroblasts by transforming growth factor-β

Experimental Cell Research

Volumn 334, Issue 2, 2015, Pages 246-259

  Chopra, Sunita ^a   Kumar, Neeraj ^a   Rangarajan, Annapoorni ^a   Kondaiah, Paturu ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Calcium; ERK1 2; P38; Transformation; catenin

Indexed keywords

ADIPOCYTOKINE; CHEMOKINE; CYTOKINE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROTROPHIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEIN P53; RAS PROTEIN; SMAD3 PROTEIN; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; WNT PROTEIN; WNT4 PROTEIN;

ACTIN FILAMENT; ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CELL ACTIVATION; CELL GROWTH; CELL IMMORTALIZATION; CELL TRANSFORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FIBROBLAST; FIBROSARCOMA CELL LINE; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSFORMED CELL; TUMOR CELL; WNT SIGNALING PATHWAY; 3T3 CELL LINE; ANIMAL; CELL LINE; CYTOLOGY; METABOLISM; MOUSE;

ANIMALS; CELL LINE; FIBROBLASTS; HUMANS; MICE; NIH 3T3 CELLS; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84929509167     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2015.03.001     Document Type: Article

References (54)

1. Massague J. TGF-beta in cancer. Cell 2008, 134:215-230.
2. Levy L., Hill C.S. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 2006, 17:41-58.
3. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338.
4. Hahn S.A., Seymour A.B., Hoque A.T., Schutte M., da Costa L.T., et al. Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res. 1995, 55:4670-4675.
5. Thiagalingam S., Lengauer C., Leach F.S., Schutte M., Hahn S.A., et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat. Genet. 1996, 13:343-346.
6. Hasegawa Y., Takanashi S., Kanehira Y., Tsushima T., Imai T., et al. Transforming Growth-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 2001, 91:964-971.
7. Saito H., Tsujitani S., Oka S., Kondo A., Ikeguchi M., et al. The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999, 86:1455-1462.
8. Tsushima H., Kawata S., Tamura S., Ito N., Shirai Y., et al. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996, 110:375-382.
9. Wikstrom P., Stattin P., Franck-Lissbrant I., Damber J.E., Bergh A. transforming growth factor beta 1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998, 37:19-29.
10. Pietras K., Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 2010, 316:1324-1331.
11. Tlsty T.D., Hein P.W. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev. 2001, 11:54-59.
12. Kojima Y., Acar A., Eaton E.N., Mellody K.T., Scheel C., et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. USA 2010, 107:20009-20014.
13. Bissell D.M. Chronic liver injury, TGF-beta, and cancer. Exp. Mol. Med. 2001, 33:179-190.
14. Serini G., Gabbiani G. Mechanisms of myofibroblast activity and phenotypic modulation. Exp. Cell Res. 1999, 250:273-283.
15. Hashimoto S., Gon Y., Takeshita I., Matsumoto K., Maruoka S., et al. transforming growth factor-beta 1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway. Am. J. Respir. Crit. Care Med. 2001, 163:152-157.
16. Roberts A.B., Anzano M.A., Wakefield L.M., Roche N.S., Stern D.F., et al. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc. Natl. Acad. Sci. USA 1985, 82:119-123.
17. Massague J. The transforming growth factor-beta family. Annu. Rev. Cell Biol. 1990, 6:597-641.
18. Chatani Y., Tanimura S., Miyoshi N., Hattori A., Sato M., et al. Cell type-specific modulation of cell growth by transforming growth factor beta 1 does not correlate with mitogen-activated protein kinase activation. J. Biol. Chem. 1995, 270:30686-30692.
19. Siegel P.M., Shu W., Cardiff R.D., Muller W.J., Massague J. transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl. Acad. Sci. USA 2003, 100:8430-8435.
20. Roberts A.B., Tian F., Byfield S.D., Stuelten C., Ooshima A., et al. Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev. 2006, 17:19-27.
21. Zhang Y.E. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009, 19:128-139.
22. Lee M.K., Pardoux C., Hall M.C., Lee P.S., Warburton D., et al. TGF-beta activates ERK MAP kinase signalling through direct phosphorylation of ShcA. EMBO J. 2007, 26:3957-3967.
23. Yu L., Hebert M.C., Zhang Y.E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 2002, 21:3749-3759.
24. Wilkes M.C., Murphy S.J., Garamszegi N., Leof E.B. Cell-type-specific activation of PAK2 by transforming growth factor beta independent of Smad2 and Smad3. Mol. Cell Biol. 2003, 23:8878-8889.
25. Caraci F., Gili E., Calafiore M., Failla M., La Rosa C., et al. TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol. Res. 2008, 57:274-282.
26. Wilkes M.C., Leof E.B. Transforming growth factor beta activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. J. Biol. Chem. 2006, 281:27846-27854.
27. Wilkes M.C., Mitchell H., Penheiter S.G., Dore J.J., Suzuki K., et al. Transforming growth factor-beta activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res. 2005, 65:10431-10440.
28. Verrecchia F., Chu M.L., Mauviel A. Identification of novel TGF-beta /Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J. Biol. Chem. 2001, 276:17058-17062.
29. Chambers R.C., Leoni P., Kaminski N., Laurent G.J., Heller R.A. Global expression profiling of fibroblast responses to transforming growth factor-beta 1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am. J. Pathol. 2003, 162:533-546.
30. Yang Y.C., Piek E., Zavadil J., Liang D., Xie D., et al. Hierarchical model of gene regulation by transforming growth factor beta. Proc. Natl. Acad. Sci. USA 2003, 100:10269-10274.
31. Ranganathan P., Agrawal A., Bhushan R., Chavalmane A.K., Kalathur R.K., et al. Expression profiling of genes regulated by TGF-beta: differential regulation in normal and tumour cells. BMC Genomics 2007, 8:98.
32. Bae D.S., Blazanin N., Licata M., Lee J., Glick A.B. Tumor suppressor and oncogene actions of TGFβ1 occur early in skin carcinogenesis and are mediated by Smad3. Mol. Carcinog. 2009, 48(5):441-453.
33. Sheed S., Nelson-Rees W.A., Toth E.M., Arnstein P., Gardner M.B. Characterisation of a newly derived human sarcoma cell-line (HT-1080). Cancer 1974, 33:1027-1033.
34. Rangarajan A., Hong S.J., Gifford A., Weinberg R.A. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 2004, 6:171-183.
35. Khan I., Kumar N., Pant I., Narra S., Kondaiah P. Activation of TGF-β pathway by areca nut constituents: a possible cause of oral submucous fibrosis. Plos One 2012, 7(12):e51806.
36. Smyth G.K., Speed T. Normalization of cDNA microarray data. Methods 2003, 31:265-273.
37. Saeed A.I., Bhagabati N.K., Braisted J.C., Liang W., Sharov V., Howe E.A., et al. TM4 microarray software suite. Methods Enzymol. 2003, 411:134-193.
38. Jonk J.C., Itoh S., Heldin C.H., Dijke P., Kruijer W. Identification and Functional characterization of a smad binding element (SBE) in the JunB promoter that acts as the transforming growth factor-β/activin and bone morphogenetic protein inducible enhancer. J. Biol. Chem. 2000, 273:21145-21152.
39. Wrana J.L., Attisano L., Carcamo J., Zentella A., Doody J., et al. TGF-β signals througha heteromeric protein complex. Cell 1992, 71(6):1003-1014.
40. Pearson G., Robinson F., Beers Gibson T., Xu B.E., Karandikar M., et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 2001, 22:153-183.
41. Lewis T.S., Shapiro P.S., Ahn N.G. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 1998, 74:49-139.
42. The WNT homepage. http://web.stanford.edu/group/nusselab/cgi-bin/wnt/main.
43. Veeman M.T., Axelrod J.D., Moon R.T. A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev. Cell 2003, 5:367-377.
44. Kohn A.D., Moon R.T. Wnt and calcium signaling: beta-catenin-independent pathways. Cell Calcium 2005, 38:439-446.
45. Itaranta P., Chi L., Seppanen T., Niku M., Tuukkanen J., et al. Wnt-4 signaling is involved in the control of smooth muscle cell fate via Bmp-4 in the medullary stroma of the developing kidney. Dev. Biol. 2006, 273:473-483.
46. 2+ waves and enhances gene expression in human pulmonary fibroblasts. Am. J. Respir. Cell Mol. Biol. 2012, 46:757-764.
47. 2+ influx involves the type III IP3 receptor and regulates actin cytoskeleton. Am J. Physiol. Ren. Physiol. 2002, 282:F910-F920.
48. Nik S.A., Ebrahim R.P., Dam K.V., Cassiman J.J., Tejpar S. TGF-β modulates β-Catenin stability and signaling in mesenchymal proliferations. Exp. Cell Res. 2007, 313:2887-2895.
49. Cheon S.S., Wei Q., Gurung A., Youn A., Bright T., et al. Beta catenin regulates wound size and mediates the effect of TGF-beta in cutaneous healing. FASEB J. 2006, 20:692-701.
50. Labbe E., Letamendia A., Attisano L. Association of smads with LEF1/TCF mediates cooperative signaling by the TGF-beta and the WNT pathways. Proc. Natl. Acad. Sci. 2000, 97(15):8358-8363.
51. Galliher A.J., Schiemann W.P. Src Phosphorylates Tyr284 in TGF-B Type II receptor and regulates TGF-B stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res. 2007, 67:8.
52. Hartsough M.T., Mulder K.M. Transforming growth factor-β activation of p44 MAPK in proliferating cultures of epithelial cells. J. Biol. Chem. 1995, 120:7117-7124.
53. Naz S., Bashir M., Ranganathan P., Bodapati P., Santosh V., et al. Pro-tumorigenic actions of S100A2 involve regulation of PI3/AKT signaling and functional interaction with smad3. Carcinogenesis 2014, 35(1):14-23.
54. Naz S., Ranganathan P., Bodapati P., Shastry A.H., Mishra L.N., et al. Regulation of S100A2 expression by TGF-beta induced MEK/ERK signaling and its role in cell migration/invasion. Biochem. J. 2012, 447(1):81-91.